Personalized Cancer
Drug Screening
Advanced bio-organoid technology for personalized cancer treatment and drug discovery. Our platform offers rapid, scalable screening in a human-relevant non-animal model, guiding precision oncology strategies.
About Our Platform
Personalized Cancer Drug Screening
Using bio-organoids, we perform personalized cancer drug screening by exposing 3D tissue models to panels of therapies to assess efficacy and resistance. These organoids faithfully recapitulate tumor architecture, microenvironment, and genetics, enabling clinically relevant predictions.
Our platform offers rapid, scalable screening in a human-relevant non-animal model, guiding precision oncology strategies. Partner with us to translate your drug pipeline into individualized therapeutic insights.
Faithful Recapitulation
Organoids replicate tumor architecture, microenvironment, and genetics for accurate predictions.
Clinically Relevant
Human-relevant non-animal models that guide precision oncology strategies.
Scalable Platform
Rapid, scalable screening to translate drug pipelines into individualized therapeutic insights.
Our Process
From Biopsy to Insights
Patient Biopsy Collection
Tumor biopsy samples are collected and processed for organoid derivation.
Organoid Development
3D bio-organoids are grown faithfully recapitulating the original tumor architecture.
Drug Panel Screening
Organoids are exposed to panels of therapies to assess efficacy and resistance patterns.
Data & Insights
Clinically relevant predictions delivered to guide precision oncology strategies.
Why Choose Us
Why Choose Our Platform
Cutting-edge technology meets clinical precision for personalized cancer treatment.
Advanced Technology
State-of-the-art bio-organoid models for accurate drug response prediction.
Precision Focused
Personalized screening tailored to individual patient profiles and tumor characteristics.
Rapid Results
Fast turnaround times without compromising on accuracy or clinical relevance.
Ready to Transform Cancer Treatment?
Partner with us to leverage personalized cancer drug screening for precision medicine and improved patient outcomes.